ESMO Congress 2026

Treating according to the molecular profile rather than the tumor site is a route in precision oncology that has been tested repeatedly: since the 2015 Precision Medicine Initiative put its near-term focus on cancers ^[4], the TAPUR study extended the target landscape from V600E to all BRAF alterations ^[2]; the WINTHER trial navigated therapy with fresh-biopsy 236-gene DNA sequencing (arm A) or tumor-versus-normal RNA expression comparison (arm B) — of 303 consented patients, 107 were evaluable; the rate of stable disease ≥6 months plus partial or complete response was 26.2% (arm A 23.2%, arm B 31.6%, P = 0.37), and the proportion with a WINTHER-versus-previous-therapy PFS ratio >1.5 was 22.4%, which did not meet the pre-specified primary endpoint ^[6]; in prostate cancer, tissue biomarker tests such as ConfirmMDx, Promark, Oncotype DX, and Decipher are already used for diagnosis, prognosis, and treatment decisions ^[3].

What the ESMO 2026 live posts relayed was a talk from an ESMO therapeutic landscapes webinar: the speaker asked "what if we treated the molecular profile, not just the tumor site," arguing that tumor agnostic therapies are redefining precision oncology, making comprehensive genomic profiling and biomarker-driven decisions increasingly important, and explicitly naming the challenge as translating molecular findings into meaningful clinical benefit. The live post disclosed no specific trial names or numbers. Another live post came from LARVOL, saying it appeared at ESMO 2026 as the "purple tiger," promoting smarter oncology decisions and healthcare AI, likewise with no data. There is no main-site news for this topic so far, so there is nothing from independent coverage to confirm or add.

Relative to what is already published, what this meeting advances is less new evidence than a shift of emphasis: WINTHER already showed that not all tumors carry tractable genomic alterations, and transcriptomic comparison is a complementary path with limited overall benefit ^[6]; this discussion pushes the focus from "whether molecular alterations can be detected" to "the translation from detection to clinical benefit," in line with TAPUR's move to cover all BRAF alterations ^[2] and with the direction of biomarker-guided risk stratification and treatment decisions ^[3].

The limitations are equally clear: the available material consists only of webinar-talk and exhibitor-promotion-style live posts, with no patient-level efficacy or safety readouts; the webinar speakers, specific content, and conclusions are undisclosed, and LARVOL's AI claims have no data support — judgment should wait for formal materials and subsequent reports.